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Assimilating transcriptional profiles from CCLE lesional skin and peripheral blood offers a 
comprehensive model of disease pathogenesis
R Dey-Rao and AA Sinha Dermatology, University at Buffalo, Buffalo, NY
The importance of skin manifestations in lupus erythematosus (LE) makes it vital to investigate 
cutaneous disease based on molecular criteria. To this end, our strategy includes microarray-based 
gene expression analyses of lesional skin and blood of chronic cutaneous lupus erythematosus 
(CCLE) patients to illuminate disease mechanisms and clarify the molecular genetic basis of disease 
heterogeneity. Here, we integrate gene expression data from both environments and use a functional 
and genetic approach to better understand pathomechanisms of disease. There is a significant 
upregulation of apoptosis and interferon response in both skin and blood of CCLE patients consis-
tent with reported findings in SLE supporting the hypothesis that these key pathways are relevant 
across the broad spectrum of lupus. Taken together, our data suggests a comprehensive model of 
systemic and local disturbances orchestrated as three distinct phases in the autoimmune response: 
1) initiation, 2) amplification of the immune response, and 3) target damage. Of interest, we observe 
an enrichment for heightened immune surveillance/initiation related processes in lesional skin 
than in peripheral blood of CCLE patients. Further, we identify seven regions of overlap between 
transcriptional “hot spots” found in CCLE blood and lesional skin, with several genes that do not 
correspond with reported SLE dysregulated genes or putative risk loci, thus potentially harboring 
susceptibility loci distinct for CCLE.    
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DDX6 orchestrates human epidermal progenitor function through the mRNA degradation 
and translation pathways.
G Sen, Y Wang and Y Chen Division of Dermatology, Department of Medicine, University of 
California, San Diego, La Jolla, CA
Although diseases that involve alterations in epidermal growth and differentiation impact every 
one in five people, the basis for how epidermal progenitor cells suppress premature differentiation 
and promote self-renewal is unclear. Here, we show that DDX6 is necessary to maintain self-re-
newal of the progenitor cells that reside in the basal layer of the epidermis. Depletion of DDX6 
resulted in loss of progenitor cell function due to premature differentiation and loss of proliferation. 
In-vivo progenitor cell competition assays demonstrated that DDX6 mediates self-renewal through 
cell intrinsic mechanisms. Gene expression profiling revealed that DDX6 is necessary to sustain 
proliferation while actively suppressing differentiation. To promote proliferation and self-renewal, 
DDX6 facilitates the translation of regulators of proliferation (CDK1 and HMGB2) and epigenetic 
factors necessary for self-renewal such as EZH2 and ACTL6a. DDX6 through association with mRNA 
binding protein, YBX1, bind to stem loops found in the 3’UTRs of these mRNAs and recruits them 
to EIF4E to promote translation and thus maintains the proliferative and self-renewal capacity of 
progenitor cells. To actively suppress differentiation, DDX6 regulates a GC rich region in the 5’UTR 
of KLF4, a transcription factor necessary for epidermal differentiation, and promotes its degrada-
tion through mediators of mRNA degradation such as EDC3. Collectively, our results suggest that 
DDX6 complexes maintain progenitor cell fate by facilitating the translation of mRNAs involved in 
proliferation and self-renewal while also targeting differentiation inducing mRNAs for degradation.   
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Trans-ethnic genome-wide meta-analysis identifies multiple novel associations and reveals 
ethnic heterogeneity of psoriasis susceptibility
X Yin,5 H Low,1 M Seielstad,1 W Liao,2 M Stahle,3 A Franke,4 X Zhang5 and J Liu5 1 
Genome Institute of Singapore, Singapore, Singapore, 2 School of Medicine, University of 
California, San Francisco, San Francisco, CA, 3 Department of Medicine, Karolinska Institutet, 
Stockholm, Sweden, 4 Institute of Clinical Molecular Biology, Christian-Albrechts-University 
of Kiel, Kiel, Germany and 5 Institute of Dermatology, Anhui Medical University, Hefei, China
In order to extensively identify the susceptibility genes and characterize the ethnic heterogeneity of 
psoriasis, we conducted the largest trans-ethnic genome-wide meta-analysis (GWMA) of psoriasis 
in 15,369 cases and 19,517 controls of Caucasian and Chinese ancestries. We identified four 
novel associations at rs9533962 (OR=1.12, P=7.53×10-11, LOC144817), rs34394770 (OR=1.16, 
P=2.65×10-8, COG6), rs8128234 (OR=1.17, P=3.74×10-8, RUNX1), and rs28512356 (OR=1.17, 
P=4.31×10-8, TP63), as well as three novel secondary associations within IFIH1 (rs3747517, 
ORcondition=0.78, Pcondition=1.52×10
-18) and IL12B (rs2853694, OR=1.23, P=4.24×10-10; rs4921493, 
OR=1.23, P=3.52×10-13). Fine-mapping analysis of MHC region had demonstrated an important 
role for all three HLA class I genes and a complex and heterogeneous pattern of HLA associations 
between Caucasian and Chinese populations. Further trans-ethnic comparison suggested popula-
tion-specific or allelic heterogeneity for eleven loci, and these population-specific effects contribute 
significantly to the ethnic diversity of psoriasis prevalence. This study not only provides novel 
biological insights into the involvement of immune and keratinocyte development mechanism, 
but also demonstrates a complex and heterogeneous genetic architecture of psoriasis susceptibility 
across ethnic populations.    
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RNA recognition motif of LEMD3 as a key player in the pathogenesis of Buschke–Ollendorff 
syndrome
S Takashima, Y Fujita, S Suzuki, N Saito, T Nomura and H Shimizu Department of 
Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Buschke–Ollendorff syndrome (BOS) is an autosomal dominant disease characterized by dissemi-
nated connective tissue nevi of elastic type and osteopoikilosis. BOS results from loss-of-function 
mutations in the LEMD3 gene, which encodes a potent negative regulator of the transforming growth 
factor-β and bone morphogenic protein signaling pathways. Although the pathogenic role of LEMD3 
mutations in BOS is not fully understood, the RNA recognition motif (RRM) of LEMD3, which binds 
to R-Smads, has been shown to be critical in the function of the protein in vitro. However, the 
importance of the RRM in the pathogenesis of BOS has not been verified clinically. Here we report 
a two-generation Japanese family with BOS. The proband and his younger brother had asymptom-
atic plaques on the trunk, which were histopathologically confirmed to be connective tissue nevi. 
Pelvis and hip radiographs revealed “spotted bones”, which is consistent with osteopoikilosis; their 
mother also had osteopoikilosis, without any cutaneous lesions. We performed a mutation analysis 
of LEMD3 using genomic DNA extracted from peripheral blood leukocytes. Direct sequencing of all 
exons and exon/intron boundaries of LEMD3 identified the novel frameshift mutation c.2495delG, 
which causes a premature termination codon (PTC) at 31 amino acids downstream of the mutation 
(p.Gly832Valfs*31) in the RRM. All the affected family members are heterozygous for the mutation. 
Since the PTC occurs in the last exon of the gene, the mutant LEMD3 mRNA is predicted to escape 
nonsense-mediated mRNA decay (NMD). Indeed, qRT-PCR analysis demonstrated no decrease in 
the amount of LEMD3 mRNA in the affected mother. In addition, qRT-PCR analyses for LEMD3-as-
sociated genes revealed the reduced expression of Smad6 mRNA, whereas the expression level of 
Smad7 mRNA was not diminished. Thus, this study is the first to suggest that loss of the RRM, and 
not necessarily loss of the whole LEMD3 protein by NMD, could cause characteristic BOS symptoms 
through imbalance of Smad6 and Smad7 expression.    
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Epigenetic modulation of skin equivalents by cosmetic ingredients
J Namkoong,1 DG Kern,1 R Gopaul,1 E Lehigh,2 AJ Langerveld2 and H Knaggs1 1 Global 
Research & Development, Nu Skin Enterprises, Inc., Provo, UT and 2 Genemarkers, 
Kalamazoo, MI
Numerous topical ingredients are available for formulating cosmetic products. A variety of bio-
logical assessment methods aids in the selection of cosmetic ingredients for finished products. 
Differences in the source or manufacturing process used to obtain the ingredient and the blending 
of ingredients impact biological efficacy. Modulation of gene expressions is commonly used to 
evaluate biological activities. Epigenetic changes play a significant role in how genes are expressed 
and translated into functional proteins. Epigenetics represents the heritable changes without alter-
ing DNA sequences; it is critical in biological functions, since epigenetics allows tissue-specific 
changes in gene expression. Examples of epigenetic modifications are DNA methylation, histone 
modification and regulatory RNAs. Cosmetic ingredients are evaluated for epigenomics, utilizing 
the DNA methylation arrays for more global assessments or individual genes/targets by looking 
at the specific promoter regions for histone modification or methylation patterns. High through-
put screening methods can also be used to measure expression of microRNAs, small non-coding 
regulatory RNAs that play a significant role in gene expression. A qPCR-based screening method 
was used to examine microRNAs with established roles in skin biology. This method was used to 
investigate how combinations of topical ingredients modulate gene and microRNA expression in 
full-thickness skin equivalent models. Results showed changes in several mRNAs gene expression, 
with some correlated changes in microRNAs, such as SIRT1 stimulation through the inhibition of 
miR-9. Additional correlations between epigenetic modulation and mRNA gene expression that 
influence skin aging are being investigated.    
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The lncRNA FLJ46906 alters expression of aging-associated proteins through binding to AP-1 
and NF-κB
K Yo1, 2 and TM Ruenger1 1 Dermatology, Roger Williams Medical Center, Boston University, 
Providence, RI and 2 Dermatological R&D, POLA Chemical Industries, Yokohama, Japan
Aged and young cells are characterized by different gene expression profiles, but the mechanisms 
of altered gene expression in aged cells remain incompletely understood. Long non-coding RNA 
(lncRNA) is a recently described class of RNA. Some lncRNAs are involved in gene regulation, e.g. 
during development and tumorigenesis, but the functions of most of the lncRNAs remain unknown. 
We hypothesized that lncRNAs are responsible for altered gene expression in aged cells. Using 
dermal fibroblasts from a young and an old donor and a DNA microarray that contains probes for 
more than 7,000 lncRNAs, we screened for differentially expressed lncRNAs. Out of 63 either up- or 
down-regulated lncRNAs, one lncRNA, called FLJ46906, was confirmed by qPCR to be consistently 
upregulated (3-fold) when comparing cells from several young and old donors. The function of this 
lncRNA was unknown. Some lncRNAs affect expression of neighboring genes, but the expression 
of protein-coding genes in the vicinity of FLJ46906 was not found to be altered. To discover its 
function, FLJ46906 was then knocked down in fibroblasts using siRNA to investigate its impact on 
aging-associated proteins. While the expression of MMPs and COL1α were not affected, expression 
of IL-1, 6, 8, TNF-α and p21 mRNAs was decreased and expression of TGF-β and elastin mRNAs 
increased. As the expression of these genes is typically altered in aged cells, these results suggest that 
FLJ46906 mediates aging in fibroblasts. As these proteins have in common that they are regulated 
by the inflammatory transcription factors AP-1 and NF-κB, we hypothesized that FLJ46906 binds to 
these factors. This was confirmed by results of RNA immunoprecipitation assays that showed strong 
and specific binding of FLJ46906 to AP-1 and NF-κB. In summary, our data demonstrate that the 
lncRNA FLJ46906 alters expression of crucial, aging-associated proteins through binding to AP-1 
and NF-κB and support the hypothesized role of lncRNAs in the aging process.    
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TALEN-induced mutations confirm Col17a1 as a genetic modifier of junctional epidermolysis 
bullosa in mice
TJ Sproule,1 JP Sundberg,1 BE Low,3 KA Silva,1 D Reyon,2 K Joung,2 MV Wiles1 and 
DC Roopenian1 1 Department of Research and Development, The Jackson Laboratory, Bar 
Harbor, ME, 2 Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, MA 
and 3 Biogen Idec, Cambridge, MA
Normal allelic variation in the NC4 domain encoded by Col17a1 exon 50 affects the onset and 
severity of Lamc2jeb induced junctional epidermolysis bullosa (JEB) in mice. Mouse mutations result-
ing from TALEN targeting of Col17a1 intron 50-51 and exon 50, including a 2 SNP replacement 
event confirming the modifier role of S1275G and N1277S AA variation, a 10 bp exonic frame 
shift deletion which acts as a loss of function mutation, and multiple nested short and long in 
frame deletions focused on putative key binding sites. Despite the apparent importance of NC4 to 
collagen 17/laminin 332 binding and the fact that many Col17a1 mutations can result in JEB, mice 
homozygous for any of these in frame deletions are normal. However, greatly accelerated disease 
is seen in mice homozygous for the Lamc2jeb mutation when combined with Col17a1em1Dcr whole 
exon 50 deletions in either the heterozygous or homozygous state. Likewise, heterozygosity for the 
em8 frame shift mutation alone has no notable effect but combining it with homozygosity for the 
Lamc2jeb mutation accelerates disease. Combinations of smaller 9-18 bp Col17a1 exon 50 deletions 
at putative key binding sites with Lamc2jeb/jeb fail to accelerate disease and in some cases actually 
alleviates symptoms. This expands knowledge of the epistatic interplay between epidermolysis 
bullosa disease-causing alleles such as Lamc2jeb and relatively innocuous allelic variants of Col17a1 
which, when combined, greatly alter disease progression. It also highlights the surprising finding that 
removal of this relatively important and interactive region of the collagen 17 protein has little or no 
visible effect in the context of healthy alleles of Lamc2 and other basement membrane components.   
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Somatic activating RAS mutations cause vascular tumors including pyogenic granuloma
YH Lim1, 3, 5, S Douglas,2 CJ Ko1, 3, R Antaya1, 4, J McNiff1, 3, J Zhou,1 RP Lifton,5 D Narayan2 
and KA Choate1, 3, 5 1 Dermatology, Yale School of Medicine, New Haven, CT, 2 Plastic 
Surgery, Yale School of Medicine, New Haven, CT, 3 Pathology, Yale School of Medicine, 
New Haven, CT, 4 Pediatrics, Yale School of Medicine, New Haven, CT and 5 Genetics, Yale 
School of Medicine, New Haven, CT
Lobular capillary hemangiomas (LCH) are vascular tumors featuring lobes of small caliber vessels. 
While the term LCH is commonly used as a synonym for pyogenic granuloma (PG), LCH as a class 
encompasses a variety of other lobular vascular lesions including infantile hemangiomas and tufted 
angiomas. For sporadic lesions such as PG, it has been proposed that lesions may be reactive to 
trauma, infection, medication and inflammation, though many PGs in uninjured skin have also 
been described. Treatment is limited to steroids or surgery, and, most recently, β-blockers, although 
nearly half of vascular tumors including LCH fail to respond. The genetic cause of many LCH lesion 
types is unknown. Therefore, we employed whole exome sequencing of two vascular tumors with 
lobular architecture and found somatic activating mutations in KRAS or NRAS in each. Recognizing 
that sporadic PGs share the lobular architecture found in these tumors, we screened 40 archival 
samples and identified activating HRAS mutations in 10% of them (4/40). Our findings of somatic 
activating RAS mutations in these lobular hemangiomas and PG lesions suggest that a subset of 
vascular tumors are driven by oncogenic RAS activation, and provides potential opportunities to 
develop targeted therapies to current drug-resistant lesions.    
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Gasdermin A3 targets mitochondria to mediate keratinocyte necrosis and skin inflammation
P Lin,1 H Lin,1 S Wu,1 C Kuo1 and L Yang1, 2 1 Inst. of Cellular and System Medicine, National 
Health Research Institutes, Zhunan, Taiwan and 2 Graduate Inst. of Molecular Systems 
BioMedicine, China Medical University, Taichung, Taiwan
The epidermis forms a critical physical and immune barrier, which could be compromised by 
deregulated responses of keratinocyte to external stimuli and ensuing inappropriate cell death. GAS-
DERMIN A (GSDMA) was involved in gastric epithelial apoptosis and has been implicated in airway 
hyperresponsiveness. Its function in the skin was indicated by dominant mutations in gasdermin A3 
(Gsdma3), which caused inflammation-mediated epidermal hyperplasia and hair loss in mice. The 
mechanisms of Gsdma3’s action and pathogenesis are unknown. Here, we showed that Gsdma3 is 
regulated by intramolecular fold-back inhibition, which is disrupted by dominant mutations in the 
C-terminal domain. The unmasked N-terminal domain of Gsdma3 then associates with Hsp90 and 
is delivered to mitochondrial via the mitochondrial import receptor Tom70, where it interacts with 
the mitohcondrial chaperone Trap1 and causes oxidative stress-mediated mitochondrial permea-
bility transition and caspase-independent cell death. Using an inducible transgenic mouse model, 
we demonstrated that epidermis-specific expression of Gsdma3 caused spontaneous keratinocyte 
necrosis and sterile skin inflammation in vivo. In primary keratinocytes isolated from the transgenic 
mice, Gsdma3 expression caused mitochondrial oxidative stress and necrosis. We hypothesized that 
Gsdma3 functions as a stress sensor, which regulates the susceptibility of keratinocytes to necrosis 
and its deregulation leads to chronic inflammatory skin diseases.    
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Genome wide association study of psoriasis in India
RP Nair,1 LC Tsoi,2 M Ghosh,3 PE Stuart,1 M Kabra,3 T Tejasvi,1 JJ Voorhees,1 G Abecasis,2 
VK Sharma4 and JT Elder1, 5 1 Dermatology, University of Michigan, Ann Arbor, MI, 2 
Biostatistics, University of Michigan, Ann Arbor, MI, 3 Pediatric Genetics, AIIMS, New Delhi, 
India, 4 Dermatology, AIIMS, New Delhi, India and 5 Ann Arbor Veterans Administration 
Hospital, Ann Arbor, MI
Genome wide association studies (GWAS) have identified over 40 psoriasis susceptibility loci in 
European ancestry populations and 17 in Chinese. Suggestive of genetic heterogeneity, only 9 loci 
overlap between these two populations. We performed a GWAS of 953 psoriasis cases and 858 
controls collected in India on the Illumina OmniExpressExome array. Principal component (PC) 
analysis showed that the samples are genetically similar to HapMap Gujarati Indian samples. We 
performed association testing using logistic regression after adjusting for the top 10 PCs. Only 
the HLA-C region on chromosome 6 showed genome wide significant association in the initial 
scan. To increase statistical power, we genotyped an additional 849 cases and 614 controls from 
India on the Illumina CoreExome array, and performed a meta analysis of the two data sets using 
735,138 markers that were genotyped in one or both datasets. Two loci achieved genome wide 
level significance (P<5E-8). The top 9 associated markers are located 30-143 kb telomeric of HLA-C, 
with the strongest associated marker, rs1265181 (OR=6.2, P=1.9E-103), located 81 kb telomeric. 
This is in contrast to Caucasian GWAS, where the strongest associated markers map centromeric 
of HLA-C. The second GW-significant signal was rs6887695 (OR=1.5, P=2.1E-12) near IL12B, an 
established psoriasis locus. In addition to these two loci, suggestive association signals (P<10E-5) 
were observed for 18 loci, including markers near RUNX3 and NFKBIA, two loci that have been 
associated with psoriasis and/or psoriatic arthritis in European-origin populations. These data are 
currently undergoing additional refinement by imputation and will require verification using an 
expanded sample set.    
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Cutaneous neovascularization in mice with chronic proliferative dermatitis (Sharpincpdm)
H HogenEsch,1 M Sola,1 TM Stearns,2 KA Silva,3 VE Kennedy,3 LE King4 and JP Sundberg3 1 
Comparative Pathology, Purdue University College of Veterinary Medicine, West Lafayette, 
IN, 2 Department of Computational Biology, The Jackson Laboratory, Bar Harbor, ME, 3 
Department of Research and Development, The Jackson Laboratory, Bar Harbor, ME and 4 
Division of Dermatology, Vanderbilt University, Nashville, TN
Laboratory mice carrying a null mutation in the Sharpin gene develop a systemic hypereosinophilic 
syndrome with a severe inflammatory and hyperproliferative skin disease called chronic proliferative 
dermatitis. The inflammatory cells are primarily comprised of eosinophils with lesser numbers of 
macrophages and neutrophils and an increased number of mast cells. While the mutant mice appear 
clinically normal at birth, at about 4 weeks of age they begin to develop a rapidly progressive skin 
disease characterized by hair loss and thick and scaly skin. We evaluated the cutaneous vasculature 
in these mice from 2 to 10 weeks of age by histology, immunohistochemistry, and transcriptome 
analyses. While there was no obvious change in the dermal lymphatics (using LYVE1 as a marker), 
histology and immunohistochemistry using CD31 and smooth muscle actin as markers revealed 
prominent neovascularization throughout the dermis and the hypodermal adipose tissue. There was 
progressive upregulation of Vegfa, Flt1, Ccr7, Cxcr4, Pdpn and Sema3a mRNA while the expression 
of Cxcl12 and Nrp2 mRNA was decreased. Many of the proteins encoded by these genes interact 
to control angiogenesis and lymphangiogenesis. LYVE1, a marker of lymphatic endothelial cells, 
remained low consistent with no obvious histologic change. The increased expression of Vegfa 
mRNA in SHARPIN-deficient mice suggests that VEGFA contributes to the progressive dermal and 
hypodermal fat angiogenesis observed in these mice.    
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Analysis of long non-coding RNAs highlights tissue-specific expression patterns and epigenetic 
profiles in normal and psoriatic skin
JT Elder1, 2, LC Tsoi,3 MK Iyer,4 PE Stuart,1 WR Swindell,1 JE Gudjonsson,1 T Tejasvi1, 
2, MK Sarkar,1 B Li,5 J Ding,6 JJ Voorhees,1 HM Kang,3 RP Nair,1 AM Chinnaiyan7 and 
G Abecasis3 1 Dermatology, Univ of Michigan, Ann Arbor, MI, 2 Ann Arbor VA Hosp, 
Ann Arbor, MI, 3 Biostatistics, Univ of Michigan, Ann Arbor, MI, 4 Bioinformatics, Univ of 
Michigan, Ann Arbor, MI, 5 Vanderbilt Univ, Nashville, TN, 6 Nat Inst Health, Bethesda, MD 
and 7 Pathology, Univ of Michigan, Ann Arbor, MI
 Although analysis pipelines have been developed to use RNA-seq to identify long non-coding 
RNAs (lncRNAs), most transcriptome studies of autoimmune disease to date have assessed only 
protein-coding transcripts due to lack of lncRNA functional annotation. To address this gap, we used 
RNA-seq data from 99 lesional psoriatic, 27 uninvolved psoriatic, and 90 normal skin biopsies, and 
applied computational approaches to identify and characterize expressed lncRNAs. We detect 2,942 
previously annotated and 1,080 novel lncRNAs which are expected to be skin specific. Notably, 
over 40% of the novel lncRNAs are differentially expressed and the proportions of differentially 
expressed transcripts among protein-coding mRNAs and previously-annotated lncRNAs are lower in 
psoriasis lesions versus uninvolved or normal skin. We find that many lncRNAs, in particular those 
that are differentially expressed, are co-expressed with genes involved in immune related functions, 
and that novel lncRNAs are enriched for localization in the epidermal differentiation complex. We 
also identify distinct tissue-specific expression patterns and epigenetic profiles for novel lncRNAs, 
some of which are shown to be regulated by cytokine treatment in cultured human keratinocytes. 
Together, our results implicate many lncRNAs in the immunopathogenesis of psoriasis, and provide 
a resource for lncRNA studies in other autoimmune diseases.    
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MCP-1 is overexpressed by Tsc2-null skin fibroblasts in a mouse model of tuberous sclerosis 
with targeted disruption of Tsc2
S Li,1 P Klover,1 RL Thangapazham,1 J Wang,1 J Moss2 and TN Darling1 1 Dermatology, 
Uniformed Services University of the Health Sciences, Bethesda, MD and 2 Cardiovascular 
and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of 
Health, Bethesda, MD
New targets for treating tuberous sclerosis complex (TSC) are needed since patients may not tolerate 
long-term treatment with mTOR inhibitors. Our previous studies demonstrated that fibroblast-like 
TSC angiofibroma and periungual fibroma cells produced high levels of MCP-1, a chemokine that 
promotes tumor growth by stimulating angiogenesis and increasing tumor-associated macrophages. 
To elucidate the roles of MCP-1 in TSC tumorigenesis and its relationship with loss of TSC2, we 
utilized a mouse model of TSC skin tumor developed with floxed Tsc2 alleles and the cre recom-
binase transgene under the control of a Prrx1 regulatory element (Prrx1-cre), which is selectively 
expressed in craniofacial and limb bud mesenchyme. Fibroblasts isolated from limb and ventral 
skin of mice with homozygous Tsc2 floxed alleles and the Prrx1-cre transgene (Tsc2cKO mice) 
lacked Tsc2 protein and had elevated levels of phosphorylated ribosomal protein S6, a marker of 
mTORC1 signaling. Skin fibroblasts of Tsc2cKO mice released 2.2-fold more MCP-1 into media 
than fibroblasts from control mice. Skin fibroblasts of Tsc2cKO mice incubated with rapamycin, 
a specific mTORC1 inhibitor, produced significantly less MCP-1 compared to a DMSO-treated 
control sample. The skin of Tsc2cKO mice was nearly 2-fold thicker and had more F4/80-positive 
macrophages than skin of control mice. Levels of MCP-1 in the sera of Tsc2cKO mice were 3-fold 
higher than in the sera of control mice. These results suggest that MCP-1 may play important roles 
in TSC tumorigenesis and serve as a novel target for the treatment of TSC.    
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Dsprul: A spontaneous mouse mutation in desmoplakin as a model of Carvajal-Huerta 
Syndrome
H Fairfield,1 JP Sundberg,2 CS Potter,3 LG Reinholdt,1 DE Bergstrom,1 BS Harris,1 I Greenstein,1 
SS Dadras,4 BT Liang,5 PN Schofield6 and CH Pratt1 1 Genetic Resource Sciences, The 
Jackson Laboratory, Bar Harbor, ME, 2 Research and Development, The Jackson Laboratory, 
Bar Harbor, ME, 3 The Jackson Laboratory for Genomic Medicine, Farmington, CT, 4 
Dermatology and Genetics and Developmental Biology, University of Connecticut Health 
Center, Farmington, CT, 5 Pat and Jim Calhoun Cardiology Center, University of Connecticut 
Health Center, Farmington, CT and 6 Physiology, Development, and Neuroscience, 
University of Cambridge, Cambridge, United Kingdom
Studies of spontaneous mutations in mice have provided valuable disease models and important 
insights into the mechanisms of human disease. A new, autosomal recessive mutant allele of the 
desmoplakin gene (Dsp) called ruffled (Dsprul) closely models a rare human disorder, Carvajal-Huerta 
Syndrome. Carvajal-Huerta Syndrome (CHS) is a rare cardiocutaneous disorder that presents in 
humans with woolly hair, palmoplantar keratoderma and left ventricular cardiomyopathy. CHS 
results from an autosomal recessive mutation on the 3’ end of Desmoplakin (DSP) truncating the 
full length protein. In mice, Dsprul arose spontaneously in the RB156Bnr/EiJ inbred mouse strain. 
Mutant mice have an abnormal hair coat, diffuse epidermal blistering, abnormal ECG traces and 
left ventricular fibrosis as compared to wildtype littermates. High-Throughput Sequencing (HTS) 
found an insertion at 38,288,978 bp of chromosome 13 predicted to result in a frameshift of Dsp, 
truncating the last 9.4% of the c-terminal portion of DSP (271 of 2,883 amino acids). The Dsprul 
mouse provides a new model to investigate the pathogenesis of CHS, as well as the underlying 
basic biology of the adhesion molecules coded by the desmosomal genes.    
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Meta-analysis of the TNIP1 region in psoriasis identifies two independent association signals
J Nititham,1 KE Taylor,1 R Gupta,2 R Ahn,2 KM Lee,2 H Chen,3 J Liu,4 M Seielstad,1 
A Ma,1 AM Bowcock,5 LA Criswell,1 M Stahle6 and W Liao2 1 UCSF, San Francisco, CA, 
2 Dermatology, UCSF, San Francisco, CA, 3 SJTU, Shanghai, China, 4 Genome Institute, 
Singapore, Singapore, 5 Imperial College, London, United Kingdom and 6 Karolinska, 
Stockholm, Sweden
To further understand the association of tumor necrosis factor alpha-induced protein 3 interacting 
protein 1 (TNIP1) with psoriasis, we performed a fine-mapping study of the TNIP1 gene region on 
chromosome 5. TNIP1 encodes the ABIN1 protein which plays a role in downregulating inflam-
mation mediated by the NF-kB signaling pathway. Single nucleotide polymorphisms (SNPs) in the 
TNIP1 gene region have been shown to be associated with psoriasis and other autoimmune diseases 
(AIDs) such as systemic lupus erythematosus and systemic sclerosis. Using five psoriasis cohorts of 
European descent totaling 4,704 cases and 7,805 controls, we imputed a 250kb region surround-
ing both sides of the TNIP1 gene using a combined reference panel from the Division of Cancer 
Epidemiology and Genetics (DCEG) and 1000Genomes cohorts. We meta-analyzed the association 
results of each cohort using a random-effects model. Conditional analyses were performed to find 
additional signal peaks of association. We then performed a literature search to compare our top 
SNPs to previously published TNIP1 SNPs associated with other AIDs. The meta-analysis revealed 
12 variants that exceeded a Bonferroni-corrected threshold. Our most significantly associated SNP 
is rs79901336 (odds ratio (OR) = 1.66, p= 1.84e-19). Upon conditioning on that top SNP, we found 
another independent association at rs17801328 (OR 1.68, p(cond)=7.80e-06). After comparing our 
top hits with SNPs in other autoimmune diseases, we show that the psoriasis top SNPs are on a 
different linkage disequilibrium (LD) block than the TNIP1 SNPs associated with other AIDs. We 
identified an additional novel independent signal peak near TNIP1 associated with psoriasis. The 
unique variants associated with psoriasis suggest that TNIP1 expression may be regulated by different 
variants in psoriasis compared to other AIDs.    
444
Dominant de novo GJA1 mutations cause erythrokeratodermia variabilis
L Boyden,1 B Craiglow,1 J Zhou,1 R Hu,1 E Loring,1 K Morel,2 C Lauren,2 R Lifton,1 AS Paller3 
and KA Choate1 1 Yale University School of Medicine, New Haven, CT, 2 Columbia 
University, New York, NY and 3 Northwestern University Feinberg School of Medicine, 
Chicago, IL
Genetic investigation of inherited skin disorders has informed understanding of skin self-renewal, 
differentiation, and barrier function. Disorders of keratinization (DOK), characterized by scaling 
and frequently associated additional epidermal and systemic sequelae, demonstrate significant 
phenotypic and genotypic heterogeneity. Over 70 DOK genes have been identified, and yet these 
genes explain only a portion of observed DOK phenotypes. We have recruited a cohort of over 
550 comprehensively phenotyped DOK kindreds, and are employing a tiered approach whereby 
cases are screened for mutations in known genes, and the remaining cohort is studied utilizing 
exome sequencing to facilitate novel gene discovery. One example of the success of this effort is 
the identification of a novel gene causing erythrokeratodermia variabilis (EKV), a rare, inherited skin 
disease characterized by transient figurate patches of erythema, localized or generalized scaling, 
and frequent palmoplantar keratoderma. We have found de novo missense mutations in GJA1 (gap 
junction protein alpha 1) in three unrelated, sporadic EKV subjects, two of which alter the same 
amino acid. The severe, progressive skin disease in EKV subjects with GJA1 mutations is without 
overlap with the systemic, non-epidermal disorder oculodentodigital dysplasia, also caused by dom-
inant GJA1 mutations. GJA1 encodes connexin 43 (Cx43), the most widely expressed gap junction 
protein. GJA1 mutations in EKV subjects lead to disruption of Cx43 membrane localization, and 
aggregation within the Golgi. These findings reveal a critical role for Cx43 in epidermal homeostasis, 
and provide evidence of organ-specific pathobiology resulting from different mutations within GJA1.   
445
Analysis of transcriptomes from palmoplantar pustulosis and palmoplantar pustular psoriasis 
suggests that they may not be different clinical entities
R Bissonnette,1 M Suarez-Farinas,2 C Brodmerkel,3 JF Duculan,2 KM Bonifacio2 and 
JG Krueger2 1 Innovaderm Research Inc., Montreal, QC, Canada, 2 Rockefeller University, 
New York, NY and 3 Janssen R&D, Spring House, PA
There is a controversy surrounding the existence of palmoplantar pustulosis (PPP) and palmoplantar 
pustular psoriasis (PPPP) as separate clinical entities or as variants of the same clinical entity. We 
used gene microarray to compare gene expression in patients PPP and PPPP. Skin biopsies from 
subjects with PPP (3), PPPP (6), psoriasis vulgaris (10) and acral skin from normal subjects (7) 
were analyzed using gene microarray. Principal component analysis showed that PPP and PPPP 
were different from psoriasis vulgaris and normal acral skin. However gene expression of PPP 
and PPPP clustered together. Gene-wise comparison between PPP and PPPP found no gene to be 
differentially expressed with a false discovery rate lower than 0.6. Surprisingly we found a higher 
expression of several genes usually expressed in the central or peripheral and nervous system 
(e.g. GPRIN, ADAM23 and RIMS3) in PPP/PPPP as compared to psoriasis vulgaris and normal 
acral skin. Immunohistochemistry confirmed these findings and showed that these proteins were 
mostly located in keratinocytes. In conclusion PPP and PPPP could not be differentiated using 
gene microarray suggesting that they may not be distinct clinical entities. Increased expression of 
GPRIN1, ADAM23 and RIMS3 in keratinocytes warrants further evaluation of their potential role 
in the pathogenesis of PPP/PPPP.    
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Psoriasis drug development and GWAS interpretation through in silico analysis of transcrip-
tion factor binding sites
WR Swindell,1 MK Sarkar,1 PE Stuart,1 JJ Voorhees,1 JT Elder1, 2, A Johnston1 and 
JE Gudjonsson1 1 Dermatology, University of Michigan, Ann Arbor, MI and 2 Ann Arbor 
Veterans Affairs Hospital, Ann Arbor, MI
Psoriasis is a cytokine-mediated skin disease that can be treated effectively with immunosuppressive 
agents. These medications, however, are not equally effective in all patients and are poorly suited 
for treating mild psoriasis. To develop more targeted therapies, interfering with transcription factor 
(TF) activity is a promising strategy. We have therefore compiled a dictionary of 2935 binding sites 
representing empirically-determined binding affinities of TFs and unconventional DNA-binding 
proteins (uDBPs). This dictionary was screened to identify “psoriasis response elements” (PREs) 
overrepresented in sequences upstream of genes differentially expressed (DEGs) in lesional vs. 
uninvolved skin of psoriasis patients (n = 237). We show that PRE sequences are recognized by 
IRF1, ISGF3, NF-kappaB and multiple TFs with helix-turn-helix (homeo) or other all-alpha-helical 
(high-mobility group) DNA-binding domains. Additionally, we identified a limited set of DEGs 
that encode proteins interacting with PRE motifs, including TFs (GATA3, EHF, FOXM1) and uDBPs 
(AVEN, RBM8A, GPAM). PREs were prominent within enhancer regions near cytokine-encoding 
DEGs (IL17A, IL19 and IL1B), suggesting that PREs might be incorporated into complex decoy 
oligonucleotides (cdODNs) for therapeutic purposes. To illustrate this idea, we designed a cdODN 
to concomitantly target psoriasis-activated TFs (i.e., FOXM1, ISGF3, IRF1 and NF-kappaB). Finally, 
we screened psoriasis-associated SNPs to identify risk alleles that disrupt or engender PRE motifs. 
This identified possible sites of allele-specific TF/uDBP binding and showed that PREs are dispro-
portionately disrupted by psoriasis risk alleles. These findings identify new TF/uDBP candidates and 
illustrate an in silico strategy that (i) connects transcriptome informatics to cdODN drug development 
and (ii) enhances our ability to interpret GWAS findings.    
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Buschke-Ollendorff syndrome in the absence of LEMD3 mutation
JL Owen, CE Purnadi and DA Glass Dermatology, University of Texas Southwestern Medical 
Center, Dallas, TX
Buschke-Ollendorff syndrome (BOS) is a rare disorder that classically exhibits connective tissue 
nevi (collagenomas or elastomas) and osteopoikilosis (OPK). BOS is highly penetrant, but exhibits 
variable expressivity, resulting in some patients with skin manifestations in the absence of OPK, 
especially prior to puberty. BOS is autosomal dominantly inherited, resulting from heterozygous loss-
of-function mutations in LEMD3, an inner nuclear membrane protein that antagonizes transforming 
growth factor beta (TGF-β) and bone morphogenetic protein (BMP) signaling. We present an 11-year-
old boy with multiple collagenomas without OPK, consistent with BOS. Sanger sequencing of all 13 
exons and splice sites within the LEMD3 gene failed to reveal a causative mutation. Copy number 
variation analysis showed no deletion or duplication involving the LEMD3 locus. Whole exome 
sequencing did not identify any mutations in LEMD3, nor in the TGF-β and BMP genes or their 
respective receptors. To our knowledge, this is the second report of a patient with BOS that lacks a 
mutation in the LEMD3 gene. This case highlights the potential genetic heterogeneity of BOS. Further 
studies are ongoing to determine other genes that might be responsible for a BOS-like phenotype.   
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Functional genomics of the ULBP6 locus reveals a critical role for CTCF-mediated long-range 
interactions in alopecia areata
GM DeStefano,1 L Petukhova2, 3, E Drill2, 4, Z Dai,2 L Bian,2 R Clynes2 and A Christiano1, 2 1 
Genetics and Development, Columbia University, New York, NY, 2 Dermatology, Columbia 
University, New York, NY, 3 Epidemiology, Columbia University, New York, NY and 4 
Biostatistics, Columbia University, New York, NY
Alopecia areata (AA) is among the most highly prevalent human autoimmune diseases, characterized 
by disfiguring hair loss due to the collapse of immune privilege in the hair follicle. To determine the 
genetic architecture of AA, our lab performed the first Genome-Wide Association Study (GWAS) 
and identified the ULBP3/6 locus on chr.6q25.1 (p = 5.9 x 10-24) as the most significantly associated 
region outside the HLA. The ULBP genes reside within an MHC class I-related cluster and encode 
ligands for the NKG2D cytotoxic T cell receptor. We previously reported a striking upregulation 
of these ligands in both human and mouse AA hair follicles, and more recently, demonstrated that 
CD8+NKG2D+ cells are both necessary and sufficient to induce disease in the AA mouse model. 
To identify functional variants at the ULBP3/6 locus, we performed targeted deep resequencing of 
this region on 124 AA patients and uncovered a small number of rare, non-coding variants enriched 
on GWAS risk haplotypes. Interestingly, we identified three novel variants that reside within distal 
ULBP6 regulatory elements and localize to CTCF binding sites. CTCF is an insulator involved in 
chromatin remodeling and gene repression, therefore, we postulate that ULBP6 non-coding variants 
disrupt CTCF-mediated long-range interactions required for ULBP repression in the hair follicle. In 
vivo, we find that CTCF is highly enriched at ULBP6 by ChIP-PCR on human scalp dermal fibro-
blasts, and in vitro reporter assays on this candidate region demonstrate strong repressive activity 
and responsiveness to CTCF binding. Remarkably, these CTCF-ULBP6 interactions are abrogated 
in the presence of all three AA-associated ULBP6 rare variants. Our findings implicate CTCF as a 
long-range repressor of the ULBP locus in the human hair follicle, delineating a potential functional 
role for these variants in disease susceptibility in AA.    
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Multiple facial vellus hair cysts, ear pits, lipomas, macrocephaly, joint laxity and cardiac 
defects: A novel genodermatosis?
MG Ponzo,1 M Van Allen,2 M Martinka3, 1 and JP Dutz1, 4 1 Dermatology, University of 
British Columbia, Vancouver, BC, Canada, 2 Department of Medical Genetics, University of 
British Columbia, Vancouver, BC, Canada, 3 Pathology and Laboratory Medicine, University 
of British Columbia, Vancouver, BC, Canada and 4 Child and Family Research Institute, 
University of British Columbia, Vancouver, BC, Canada
Eruptive vellus hair cysts (EVHC) often occur on the trunk and limbs. Facial involvement is uncom-
mon. Autosomal dominant inheritance has been described but associated extra-cutaneous anomalies 
have not. We describe a 4-patient kindred presenting with multiple facial vellus hair cysts, and 
an association of ear pits, lipomas, macrocephaly, joint laxity and cardiac defects. Patients were 
interviewed, examined, and photographed with consent. Evaluations performed include skin biopsy 
(3 of 4 patients), echocardiogram, and electrocardiogram. Cutaneous histopathologic examination 
confirmed the diagnosis of vellus hair cysts in all 3 affected individuals. Data on clinical findings 
(lipomas (3 of 4 patients), joint laxity (4 of 4 patients), ear pits (4 of 4 patients), cardiac defects 
(1 of 4 patients), macrocephaly (1 of 4 patients) were documented. We propose that facial EVHC 
may indicate the presence of a novel inherited autosomal dominant disorder with multisystemic 
manifestations.    
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Onychodystrophy, Palmoplantar keratoderma, and Amelogenesis imperfecta (OPA) syndrome 
caused by a homozygous mutation in CNBD2
Y Metzger,1 O Sarig,1 R Bochner,1 D Vodo,1 N Malchin,1 O Isakov,2 N Erez,1 A Gat,1 
I Goldberg,1 N Shomron,2 M Schwartz,4 I McLean,3 F Smith,3 F Rihani5 and E Sprecher1, 2 
1 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 2 Tel-Aviv University, Tel Aviv, Israel, 
3 University of Dundee, Dundee, United Kingdom, 4 PC project, Salt Lake City, UT and 5 
Prince Rashid Bin Al-Hassan Hospital, Irbid, Jordan
In the present study, we describe a previously unrecognized autosomal recessive ectodermal dyspla-
sia featuring Onychodystrophy, Palmoplantar keratoderma and Amelogenesis imperfecta (OPA) in a 
large consanguineous family. Using whole exome-sequencing analysis, we identified a homozygous 
point mutation (c.1481G>A p.R494Q) in CNBD2 (cyclic nucleotide binding domain 2) in affected 
individuals. A number of facts support a pathogenic role for this mutation: (1) the mutation was 
found to co-segregate with the disease phenotype in the affected family; (2) the mutation is predicted 
to be damaging; (3) the mutation affects a highly conserved amino acid residue (ConSeq=8, range 
1-9); (4) the mutation was not found in public databases (>8,000 individual sequences) and was not 
detected in a series of 186 population-matched healthy individuals. Confocal microscopy revealed 
that CNBD2 is normally expressed in the cytoplasm and nucleus of basal and supra-basal epidermal 
cells, follicular epithelium and nail matrix. CNBD2 was found to be up-regulated during epidermal 
differentiation in vitro. Global gene expression and pathway analyses revealed that down-regula-
tion of CNBD2 expression in primary keratinocytes resulted in disturbed expression of epidermal 
differentiation genes as well as down-regulation of TP63 (and many of its target genes), WNT10a 
and GJA1, which all encode important mediators of ectodermal differentiation. Taken together, the 
present results reveal a central role for CNBD2 during ectodermal differentiation.    
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The BAF/SWI/SNF complex controls genome accessibility to p63 during epidermal 
differentiation
X Bao,1 A Rubin,1 K Qu,1 J Zhang,1 P Giresi,1 H Chang1, 3 and P Khavari1, 2 1 Stanford 
University, Stanford, CA, 2 VA Palo Alto, Palo Alto, CA and 3 HHMI, Stanford, CA
“Open” and “closed” chromatin states impact gene expression by rendering genomic regions either 
accessible for expression or by repressing them, respectively. Chromatin remodeling complexes, 
such as the BAF (SWI/SNF) complex, control the transition between these open and closed states. In 
epidermis, BAF catalytic subunits, Brg1 and Brm, are required for differentiation and are frequently 
mutationally inactivated in SCC; however, how BAF acts to control differentiation in homeostasis 
and cancer is unknown. To address this, we mapped chromatin accessibility genome-wide in the 
presence or absence of functional BAF using ATAC-seq. We found that BAF is required to main-
tain accessibility of 6.8% of total open chromatin regions during epidermal differentiation. Motif 
searches of these BAF-dependent regions identified a striking enrichment of the p63 DNA binding 
motif (p=1X10-209). mRNA profiling indicates a significant overlap between the target gene sets 
of p63 and BAF (p=2.6x10-105) with the 424 co-regulated genes enriched for top gene ontology 
(GO) terms including “epidermal development” (p=3.9x10-9) and “epidermal cell differentiation” 
(p=1x10-5). Our ATAC-seq studies demonstrated that BAF loss led to loss of accessibility, at 40 
basepair average compaction, selectively at p63 binding sites. Binding sites of other factors, such 
as CTCF, was unaffected, underscoring that BAF effects on genome accessibility are selective for 
p63. BAF loss decreased p63 genome binding at its target sites and vice versa, demonstrating that 
genomic binding by p63 and the BAF complex is cooperative. Genome-wide ChIP-seq analysis of 
active and repressive marks indicates that BAF loss also decreases marks of active chromatin, such 
as H3K27Ac, p300, and RNA Pol II, at p63 binding sites, while increasing the repressive H3K27me3 
mark at these sites. Therefore our data demonstrates that the BAF complex and p63 cooperatively 
bind to maintain open chromatin and promote epidermal differentiation.    
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Novel regulatory variants identified in adult atopic dermatitis by targeted deep sequencing 
alter enhancer function
A Quiggle,1 T Marfatia,1 KJ Gulewicz,1 A Shemer,2 Z Goodwin,1 W Jones,1 E Guttman-
Yassky3 and C de Guzman Strong1 1 Washington University SOM, St. Louis, MO, 2 Tel-Aviv 
University, Tel-Aviv, Israel and 3 Icahn School of Medicine, New York, NY
Atopic Dermatitis (AD) is a common heritable, inflammatory skin disease. Although filaggrin (FLG) 
mutations are a strong risk factor for AD, susceptibility loci (1q and 11q) underscore additional 
genetic factors. Motivated by recent studies identifying enrichment for noncoding regulatory vari-
ation in common disease, we hypothesized a role for 1q and 11q regulatory variants in AD using 
targeted next-generation sequencing (NGS). We prioritized variant discovery in adult patients of a 
specific AD endotype - baseline skin barrier impairment (downregulation of Epidermal Differentia-
tion Complex [EDC] genes) and immune abnormalities. Long-range PCR genotyping revealed fewer 
FLG intragenic monomer repeats in AD patients vs. controls (p=0.018) and few FLG mutations. Tar-
geted NGS of 5 ENCODE-annotated enhancers and 4 functional regulatory elements (REs) in linkage 
disequilibrium with GWAS SNPs (rs877776, 1q21; rs7927894, 11q13.5) identified 17 regulatory 
variants (15 common SNPs, 2 novel EDC variants) in our pooled AD cases. Multiplex Sequenom 
genotyping assigned the novel EDC regulatory variants (in RE 180 and 184) to 2 independent patients 
with severe AD (SCORAD >50). Family pedigree analysis for proband 2 demonstrated segregation 
of the novel RE 184 variant with disease but with incomplete penetrance. Pairwise comparisons 
between minor and major regulatory alleles in cell-based reporter assays revealed greater effect 
sizes for the novel compared to the common minor variants. Moreover, chromatin conformation 
capture studies identified specific chromatin interactions with target EDC genes for RE 180 and 184. 
Many of the identified target genes are differentially expressed in the two patients that each harbor 
the respective novel variant. To our knowledge, our study is the first to report a functional role for 
novel regulatory variants in a distinct molecular endotype for AD and increases our understanding 
of the genetic architecture of AD.    
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Guanine nucleotide binding protein alpha q polypeptide (GnaqM1J): An ENU induced mutant 
allele affecting dermal melanocytosis in the mouse
CS Potter,1 L Dionne,2 H Fairfield,2 SS Dadras,3 JP Sundberg4 and CH Pratt2 1 The Jackson 
Laboratory for Genomic Medicine, Farmington, CT, 2 Genetic Resource Sciences, The 
Jackson Laboratory, Bar Harbor, ME, 3 Dermatology and Genetics and Developmental 
Biology, University of Connecticut Health Center, Farmington, CT and 4 Research and 
Development, The Jackson Laboratory, Bar Harbor, ME
In an N-ethyl-N nitrosourea (ENU) mutagenesis screen at The Jackson Laboratory, a colony of 
C57BL/6J mice was examined with unusually darkly pigmented skin on the body, tail, ears, lower 
legs, and foot pads. Histological examination revealed increased interfollicular epidermal pigmen-
tation and dermal pigmentary incontinence not seen in wild type littermates. Sequencing identified 
an A to G missense mutation in exon 2 in the Gnaq (Guanine Nucleotide Binding Protein (G 
Protein), Q Polypeptide) gene. Previously reported ENU induced mutations in Gnaq (GnaqMhdadsk1 
and GnaqMhdadsk10) also showed increased pigmentation of the skin, but hyperpigmentation was 
limited to the dermis, unlike the GnaqM1J allele. Somatic mutations in Gnaq were recently linked 
to Sturge-Weber Syndrome, port wine stains, blue melanocytic nevi, and dermal melanocytosis 
(Mongolian spots). This new allelic mutation provides yet another tool to study the development 
and maturation of melanocytes in the skin.    
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Skin fragility of the wild-derived, inbred mouse strain Mus pahari
T Sproule,1 CH Pratt,2 S Karst,2 DC Roopenian1 and JP Sundberg1 1 Research and 
Development, The Jackson Laboratory, Bar Harbor, ME and 2 Genetic Resource Sciences, 
The Jackson Laboratory, Bar Harbor, ME
Mus pahari is a wild-derived, inbred strain of mouse imported to The Jackson Laboratory from 
the National Cancer Institute (NCI) in 1995. It is primarily used in the field of virology because of 
a functional xenotropic and polytropic retrovirus receptor 1 (Xpr1) gene which makes this strain 
susceptible to xenotropic murine leukemia virus-related virus (XMRV). For many years, M. pahari 
colony managers have known about the fragility of this strain’s skin resulting in separation of tail skin 
from the mouse if handled incorrectly. Tail skin tension testing of M. pahari resulted in significantly 
lowered force threshold in comparison to closely related inbred mouse species and subspecies. 
Histologically the tail skin separated at the subdermal level with the dermis firmly attached to the 
epidermis, excluding the epidermolysis bullosa complex of diseases. The dermal collagen bundles 
were abnormally thickened and branched. Elastin fiber deposition was focally altered in the dermis 
adjacent to the hair follicle. Collagens present in the skin could not be differentiated between the 
species in protein gels. Together these data suggest that M. pahari have altered extracellular matrix 
development resulting in separation of the skin below the level of the dermis with moderate force 
similar to the African spiny mouse (Acomys).    
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Mouse models of skin and adnexal diseases in the Mouse Mutant Resource (MMR) at The 
Jackson Laboratory
CH Pratt,1 L Dionne,1 LG Reinholdt,1 DE Bergstrom,1 H Fairfield,1 BS Harris,1 S Karst1 and 
JP Sundberg2 1 Genetic Resource Sciences, The Jackson Laboratory, Bar Harbor, ME and 2 
Research and Development, The Jackson Laboratory, Bar Harbor, ME
The Mouse Mutant Resource (MMR) at The Jackson Laboratory (JAX) has been in existence for 
over 50 years with continuous support by the National Center for Research Resources (NCRR) 
since 1978. Mice carrying spontaneous mutations have been a rich resource for productive skin 
and adnexal disease research since the early 1900s. Despite the capability in recent decades to 
genetically engineer mouse models, strains harboring spontaneous mutations affecting the skin 
and adnexa continue to provide the raw material for in-depth investigator-initiated research, broad 
phenotypic insight, nucleotide-level functional annotation of the mouse genome and faithful mod-
eling of common and rare human genetic disorders. The hundreds of thousands of mice on the 
JAX campus on any given day, and the millions of mice produced over the course of a year, offer a 
unique and powerful opportunity for the dermatology research community to access spontaneous 
mutation mouse models. Within such large populations, spontaneous mutations inevitably occur, 
and at a detectable rate not fully appreciated in smaller colonies. These spontaneous mutations are 
manifested in mice (known as phenotypic deviants) with rare, unusual and biomedically relevant 
skin phenotypes. The JAX MMR has an established and productive program for discovering, char-
acterizing and distributing these models to dermatology researchers worlwide.    
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Inherited LCK deficiency causes susceptibility to EV-HPV infections and early-onset squamous 
cell carcinoma
S Li,1 L Duo2, 3, 4, H Wang2, 3, 4, W Dai,1 W Zhang,1 E Zhou2, 3, X Cao2, 3, 4, J Zhao2, 3, S Guo,1 
Y Xu,1 T Zhao,1 Y Xiao,1 C Ma,1 L Xia,5 Z Yang,6 L Zheng,7 Y Hu,7 C Feng2, 3, J Yin2, 3, G Xu2, 
3, Z Lin2, 3, T Gao,1 Y Yang2, 3, 4 and C Li1 1 Department of Dermatology, Xijing Hospital, 
Fourth Military Medical University, Xi’an, China, 2 Department of Dermatology, Peking 
University First Hospital, Beijing, China, 3 Beijing Key Laboratory of Molecular Diagnosis 
on Dermatoses, Beijing, China, 4 Peking-Tsinghua Center for Life Sciences, Beijing, China, 
5 Department of Dermatology, General Hospital of Ningxia Medical University, Yinchuan, 
China, 6 Department of Radiology, General Hospital of Ningxia Medical University, 
Yinchuan, China and 7 Novogene Bioinformatics Technology Co., Ltd, Beijing, China
ABSTRACT Inherit edepidermodysplasia verruciformis (EV) is a rare skin disorder characterized by 
susceptibility to specific types of human papilloma virus (HPVs) and is strongly associated with 
non-melanoma skin cancer. Inactivating mutations in EVER1 or EVER2 genes have been detected in 
most, but not all EV patients. In this study, we found 3 young EV siblings presenting with persistent 
EV-HPV infections, T cell defects and early-onset squamous cell carcinoma (SCC) without EVER1/2 
mutation. These specific clinical manifestations suggest that they displayed significant heterogeneity 
compared with common EV patients. Thus we applied whole exome sequencing (WES) to identify 
potential mutation(s) account for EV-HPV infections in this family. A novel homozygous splicing 
mutation has been detected in the T lymphocyte-specific protein tyrosine kinase (LCK) gene (c.188-
2A>G), which resulted in expression of only mutant but not wild-type LCK in all patients. Our results 
demonstrate mutations in LCK are associated with EV and provide new clues for the understanding 
of host defenses against HPV and better genetic counseling of EV patients.    
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Intra-familial variation in clinical phenotype of CARD14-related psoriasis
M Eskin-Schwartz4, 2, L Basel-Vanagaite1, 2, 3, M David4, 2, I Lagovsky,3 D Ben-Amitay5, 2, 
P Smirin-Yosef,3 L Atzmony4 and E Hodak4, 3, 2 1 Raphael Recanati Genetics Institute, Rabin 
Medical Center, Beilinson campus, Petah Tikva, Israel, 2 Sackler Faculty of Medicine, Tel Aviv 
University, Tel Aviv, Israel, 3 Felsenstein Medical Research Center, Rabin Medical Center, 
Petah Tikva, Israel, 4 Dermatology, Rabin Medical Center, Beilinson Hospital, Petah Tikva, 
Israel and 5 Pediatric Dermatology Unit, Schneider’s Children’s Medical Center of Israel, 
Petah Tikva, Israel
Psoriasis is a chronic multifactorial inflammatory disease involving skin, nails and joints. Recently 
monogenic forms of the disease have been described, including dominantly inherited plaque type 
and generalized pustular psoriasis, related to activating mutations in the CARD14 gene. In the 
present study we describe a family with multiple cases of dominantly inherited psoriasis, an extreme 
variability of clinical presentation (from mild plaque type to generalized pustular psoriasis) and early 
disease onset. The aim of the study was to investigate the genetic basis of psoriasis in the affected 
family members and to propose possible mechanisms for the intra-familial phenotype variability. 
Screening of the affected individuals for mutations in the coding regions and the exon-intron bound-
aries of the IL36RN, IL1RN and CARD14 genes revealed the c.349G>A [p.Gly117Ser] mutation 
in the CARD14 gene, previously reported to be associated with plaque type psoriasis. The most 
severely affected family members had three additional coding region polymorphisms (rs2066964 
[c.1641G>C; p.Arg547Ser], rs34367357 [c.1753G>A; p.Val585Ile] and rs11652075 [c.2458C>T; 
p.Arg820Trp]) in the CARD14 gene, suggesting their possible effect on the disease expression. In 
the aforementioned family early onset psoriasis co-segregated with the HLA-C*0602, indicating 
that the presence of the HLA-C*0602 could potentially modulate the time of the disease onset. 
In summary: In the current work we describe a family with CARD14-related psoriasis and discuss 
the possible influence of the specific haplotype of the affected family members on the intrafamilial 
variation in the clinical phenotype of the disease.    
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Mutations affecting keratin 10 surface exposed residues highlight the structural basis of 
phenotypic variation in epidermolytic ichthyosis
H Mirza,1 A Kumar,2 B Craiglow,1 J Zhou,1 C Saraceni,1 B Ragsdale,3 L Milstone,1 P Rehder,4 
A Ranki5 and KA Choate1 1 Dermatology, Yale University, New Haven, CT, 2 Paul 
Scherrer Institute, Zurich, Switzerland, 3 Central Coast Pathology, San Luis Obispo, CA, 
4 The Dermatology Medical Group of Oxnard and Camarillo, Oxnard, CA and 5 Helsinki 
University, Helsinki, Finland
Epidermolytic ichthyosis (EI) due to keratin-10 (KRT10) mutations is a rare, typically autosomal 
dominant, disorder characterized by erythema and blistering at birth followed by hyperkeratosis 
and less frequent blistering later in life. We identified two previously unreported KRT10 mutations 
p.Q434del and p.R441P in subjects presenting with a mild EI phenotype without skin fragility at 
birth. Both mutations occur within the mutational “hot spot” of the keratin 10 2B rod domain, adja-
cent to mutations which cause more severe phenotypes. p.Q434del and p.R441P form collapsed K10 
fibers rather than the aggregates observed in severe EI. Upon calcium-induced differentiation primary 
keratinocytes isolated from the p.Q434del case showed significantly lower apoptosis (p-value <0.01) 
compared to p.R156C primary keratinocytes as assessed by TUNEL assay. Conversely, the mitotic 
index of the p.Q434del epidermis was significantly higher compared to the severe EI epidermis 
(p-value <0.01) estimated by Ki67 staining. We sought to interrogate the pathophysiology of these 
mutations using structural modeling of interaction between K10 and its binding partner keratin-1 
(K1), but finding no reported crystal structure, we employed homology-based modeling to generate 
wild type (WT) and mutant 2B domain models. Such models suggested that the mutations in our 
p.Q434del and p.R441P subjects affect surface exposed residues of the alpha helix coiled-coil 
and cause localized disorganization of the K1-K10 heterodimer. In contrast, models of severe EI 
mutations including p.R156C suggest disruption of key inter-molecular interactions between K1 
and K10. This study provides insight into the structural basis of the phenotypic variation in EI due 
to KRT10 mutations.    
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Systems biological analysis of alopecia areata reveals master regulators of hair follicle immune 
privilege
J Chen2, 3, A Jabbari,2 JE Cerise2 and A Christiano1, 2 1 Genetics and Development, Columbia 
University, New York, NY, 2 Dermatology, Columbia University, New York, NY and 3 
Systems Biology, Columbia University, New York, NY
Alopecia areata (AA) is an autoimmune disease characterized by hair loss due to cytotoxic T-cell-me-
diated destruction of hair follicles. While aberrant immune activity clearly contributes to the disease, 
clinically, AA patients are generally otherwise healthy, suggesting that local genetic elements in the 
skin may mediate end-organ-specific infiltration recruitment. This end organ hypothesis predicts that 
the interaction between cytotoxic-T cells and the hair follicle may be mediated at least in part by 
molecular changes in the skin that cause the loss of its immune privilege from the host’s immune 
system. Gene expression analysis of an AA cohort revealed distinct molecular programs implicating 
a wide array of biological processes including, but not limited to, canonical immune-response 
signaling pathways. With hypothesis that some portion of this molecular program is required for 
immune infiltration, we sought to model the regulatory interactions leading to those molecular 
behaviors. We generated a regulatory model for the molecular behavior of skin and hair follicles 
in the context of AA using the ARACNe algorithm designed in cancer research and a microarray 
data of the skin and hair. Using these models, we have isolated specific molecular programs that 
define AA initiation and searched for the minimum number of genetic regulators required to repro-
duce these gene signatures. We have identified the transcriptional regulators IKZF1 and DLX4 as 
master regulators sufficient to induce an AA-like gene expression signature in normal cell types. 
These regulators are found aberrantly expressed in patients AA and exhibit suggestive association 
to AA in GWAS studies. Their expression in normal cells enhanced NKG2D-dependent cytotoxic 
killing in two independent cellular contexts. Using computational models, we have recreated an 
end-organ molecular regulatory program that appears sufficient to mediate and recruit an AA-like, 
T-cell-dependent immune response.    
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A role for autocrine and paracrine action of the Th1 chemokines in the pathogenesis of 
keratoderma
C Young,1 E Rorke2 and R Eckert1 1 Biochemistry and Molecular Biology, University of 
Maryland School of Medicine, Baltimore, MD and 2 Microbiology and Immunology, 
University of Maryland School of Medicine, Baltimore, MD
The underlying causes of keratoderma, a painful, disfiguring and progressive disease, are not well 
understood. Our recent studies indicate that inactivation of AP1 transcription factor activity in 
the suprabasal epidermis produces a murine phenotype that mimics human keratoderma. The 
phenotype is characterized by hyperproliferation, hyperkeratosis, parakeratosis, pseudoainhum 
of the tail and digits, and nuclear localization of loricrin. Nuclear loricrin localization and pseu-
doainhum are signature phenotypes of some types of keratoderma. We hypothesized that altered 
epidermal chemokine production may, in part, be responsible for the disease phenotype. Array 
analysis reveals a selective substantial increase in production of the interferon-gamma inducible Th1 
chemokines, CXCL9, CXCL10 and CXCL11. We proposed that these chemokines interact with the 
CXCR3 receptor to stimulate lymphocyte recruitment and keratinocyte hyperproliferation. Consistent 
with this idea, we observe enhanced epidermal T cell recruitment to the epidermis, and enhanced 
proliferation of CXCR3-positive basal keratinocytes. These findings suggest that Th1 chemokines 
may stimulate keratinocyte proliferation and promote Th1 lymphocyte accumulation to contribute 
to the keratoderma phenotype.    
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Pathway analysis and protein-protein interaction network construction provide functional 
interpretation of GWAS evidence in alopecia areata
L Petukhova and A Christiano Columbia University, New York, NY
GWAS have successfully identified 14 genomic loci with association to alopecia areata (AA) that 
range in size from 30Kb to 500Kb, containing multiple genes and regulatory features that can 
influence genes outside of the associated LD block. The major challenge in translating this evidence 
is determining which gene/s at or near a GWAS locus are causal. Pathway and network analyses 
have been used to prioritize genes at GWAS loci and provide insight into disease pathogenesis, 
implicating biological processes of etiologic importance. Here, we performed pathway analysis and 
constructed protein-protein interaction (PPI) networks for the 226 protein coding transcripts located 
within +/- 500 Kb of the most significant SNP for each GWAS locus. Enriched pathways include 
Antigen Presentation (n=16; p=3x10-12), JAK-STAT Signaling (n=10; p=9x10-4), and Costimulatory 
Signaling (n=6; p=1x10-5). Enriched gene ontology (GO) terms include MHC class II (n=12, p=1x10-
14) and class I (n=6, p=9x10-7) proteins, T-cell activation (n=10, p=1x10-5) and differentiation (n=6, 
p=4x10-4), and regulators of transcription (n=12,p=.03) and post translational modifications (n=13, 
p=.02). Also, some cellular processes that did not reach significance are implicated by genes across 
loci and include redox (10 genes, 5 loci), apoptosis (10 genes, 7 loci), and steroid hormone signaling 
(7 genes, 6 loci). Construction of a PPI network identified 40 direct connections (p=.007) among 46 
genes from 13 of the 14 GWAS loci. Allowing for a common interactor generated a single highly 
connected network (p=.002) of 148 genes from all 14 GWAS loci. The results of pathway analysis 
and PPI network construction allow us to contextualize statistical evidence from GWAS within a 
biological framework and to prioritize candidate genes for further genetic studies (e.g. targeted 
resequencing). Importantly, these results also support our ongoing clinical research which shows 
human clinical relevance for therapeutics targeted to the Costimulatory (e.g. Abatacept) and JAK/
STAT (e.g. Ruxolitinib, Tofacitinib) pathways.    
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Juxta-articular joint-capsule mineralization in CD73 deficient mice: Similarities to patients 
with NT5E mutations
Q Li,1 TP Price1, 2, D Wang,1 JP Sundberg3 and J Uitto1 1 Dermatology and Cutaneous 
Biology, Sidney Kimmel Medical College, Philadelphia, PA, 2 Surgery, Sidney Kimmel 
Medical College, Philadelphia, PA and 3 Development, The Jackson Laboratory, Bar Harbor, 
ME
Arterial calcification due to CD73 deficiency (ACDC), an autosomal recessive disorder, mani-
fests with extensive mineralization of the lower-extremity arteries as well as of hand and foot 
joint-capsules. This disease is caused by mutations in the NT5E gene which encodes CD73, a 
membrane-bound ecto-5’-nucleotidase hydrolyzing 5’-AMP into adenosine and Pi. To gain insight 
into the pathophysiologic details of ACDC, we have characterized a Nt5e-/- knock out mouse 
(Nt5etm1Jgsc) deficient in CD73. These mice, when maintained on appropriate strain background, 
demonstrated stiffening of the joints and micro computed tomography revealed distinct changes 
in the thoracic skeletal structure with evidence of mineralization at the costochondral junctions. 
Mineralization was also noted in the juxta-articular spaces of the lower extremities as well as of 
ligaments and capsules adjacent to the bony structures. No evidence of vascular mineralization 
was noted either by micro-computed tomography or by microdissection of arteries in the thoracic 
area or in lower extremities. The Nt5e-/- mutant mice demonstrated significantly increased Pi levels 
in the serum and significantly reduced PPi concentration in the heparinized plasma, resulting in 
markedly increased Pi/PPi ratio, thus creating a pro-mineralization environment. In conclusion, the 
Nt5e-/- targeted mutant mice recapitulate some, but not all, features of ACDC and serve as a model 
system to study pharmacologic interventions for ectopic vascular mineralization. Collectively, this 
mouse model deficient in CD73, with other targeted mutant mice with vascular mineralization, 
attests to the presence of a complex pro-mineralization/anti-mineralization network that under 
physiologic homeostatic conditions prevents ectopic tissue mineralization.    
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miR29b1 plays an important role in epidermal cell growth and survival 
X Zhang,1 J Wu,1 J Qin2 and JY Zhang1 1 Dermatology, Duke University, Durham, NC and 2 
IGSP, Duke University, Durham, NC
MicroRNAs (miRNAs) are a group of small noncoding RNAs that interact with specific mRNAs 
to regulate gene expression. A number of miRNAs have been characterized as key regulators of 
cell growth and survival. It is unclear how miRNAs are regulated by AP-1 gene regulators during 
epidermal growth and differentiation. In this study, we performed ChIP-seq analysis with human 
keratinocytes and identified 12 miRNAs whose gene promoter regions showed >50 fold enrich-
ment by ChIP with a c-Jun antibody. Among these, miR29b1 was highly expressed in proliferating 
keratinocytes. By RT-PCR, we found that miR29b1 level was markedly decreased upon c-Jun gene 
silencing and increased by c-Jun overexpression. Also in line with the reduced level of active c-Jun 
(namely pc-Jun), miR29b1 was decreased in response to Ca++-induced epidermal differentiation. 
Functionally, overexpression of miR29b1 rescued cells from apoptosis induced by c-Jun loss, which 
was correlated with reduced expression of Bim1, a proapoptotic molecule previously identified as 
a miR29-target in neuronal cells. Moreover, c-Jun gene silencing increased, while overexpression 
of miR29b1 decreased expression of CAMK2G, an important regulator of Ca++ signaling. Lastly, 
miR29b1 was expressed at an elevated level in A431 SCC cells compared to keratinocytes, and its 
exogenous expression prevented A431 cell death and growth arrest induced by c-Jun loss. Taken 
together, these findings indicate that miR29b1 is positively regulated by c-Jun, and plays important 
roles in cell growth and survival of both normal keratinocytes and cancer cells. Currently, our 
efforts are focused on confirming the functional importance of miR29b1 in epidermal growth and 
differentiation by using 3-D culture and skin grafting.    
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Kindler syndrome: Novel and recurrent FERMT1 mutations in 20 unique families with 70 
patients and evidence of genetic heterogeneity
L Youssefian1, 2, H Vahidnezhad1, 2, 3, MR Barzegar,4 Q Li,2 S Zeinali,1 P Mansouri,1 
MR Basiri1 and J Uitto2 1 Tehran University of Medical Sciences, Tehran, Iran (the Islamic 
Republic of), 2 Thomas Jefferson University, Philadelphia, PA, 3 Pasteur Institute of Iran, 
Tehran, Iran (the Islamic Republic of) and 4 Shahid Behesti University of Medical Sciences, 
Tehran, Iran (the Islamic Republic of)
The Kindler syndrome (KS) is a rare autosomal recessive genodermatosis characterized by diffuse 
poikiloderma, cutaneous atrophy, acrokeratosis, trauma-induced blisters and photosensitivity. Sixty 
two mutations have been previously disclosed in the FERMT1 gene in ~150 patients; this gene 
encodes kindlin-1, a component of keratinocyte focal adhesions. The incidence of KS is expected 
to be relatively high in Iran due high rate of consanguineous marriages. We examined a total of 20 
Iranian families with KS, including 70 affected individuals, including one extended family with 24 
patients. Sequencing of FERMT1 by amplification of all 15 exons and flanking intronic sequences as 
well as the promoter region, revealed 14 distinct mutations in 17 families, 11 of the mutations being 
novel. Two novel mutations, p.Q226X and c.1253delA, were found in more than 1 family (4 and 
2, respectively). Haplotype analysis of the FERMT1 region in these families indicated the presence 
of a conserved haplotype, indicating founder effect. In two families, no mutation in FERMT1 gene 
was found and autozygosity mapping excluded this locus. Careful examination of patients in these 
two families revealed unusual clinical features suggesting new entities with clinical overlapping 
features with KS. Morpholino knockdown of Fermt1 in zebrafish results in a ruptured fin phenotype, 
forming the basis to test the pathogenicity of 3 thus far identified missense mutations in FERMT1. 
Collectively, the previously unpublished mutations in the FERMT1 gene expand the spectrum of 
mutations underlying KS. The identified mutation database forms the basis to confirm the clinical 
diagnosis by genetic testing and to identify heterozygous carriers, which when coupled with genetic 
counseling can reduce the burden of KS in Iran.    
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Somatic V600E BRAF mutation causes syringocystadenoma papilliferum
J Levinsohn,1 J Sugarman,2 K Bilguvar3, 4, J McNiff5 and KA Choate1 1 Dermatology, Genetics 
and Pathology, Yale University, New Haven, CT, 2 Dermatology and Family Medicine, 
University of California, San Francisco, San Francisco, CA, 3 Genetics, Yale University, New 
Haven, CT, 4 Yale Center for Genome Analysis, Yale University, New Haven, CT and 5 
Dermatology and Pathology, Yale University, New Haven, CT
Syringocystadenoma papilliferum (SCAP) is a benign skin tumor with rare progression to malignancy 
and has histology characterized by cystic epithelial hyperplasia, papillary projections lined by 
columnar epithelium, and a plasma cell infiltration in surrounding stroma. SCAP can arise sponta-
neously as a solitary neoplasm, or may be present at birth in a linear configuration, following the 
dorsovental patterns of migration of keratinocyte precursors, known as lines of Blaschko. Expecting 
that such linear lesions result from post-zygotic mutation during early development, we performed 
whole exome sequencing of a Blaschkoid SCAP, finding a single damaging tissue-specific mutation, 
BRAF V600E. Targeted sequencing of 9 spontaneously arising SCAPs, revealed the identical BRAF 
V600E mutation in 4 additional samples. These data demonstrate that both mosaic and sporadic 
SCAP can be caused by somatic BRAF mutation and raise the possibility that rare malignant exam-
ples of SCAP lesions might respond to molecular therapeutics targeting the BRAF V600E mutation.   
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The spectrum of COL7A1 mutations identified in 63 families with dystrophic epidermolysis 
bullosa by comparative Sanger and next generation sequencing
H Vahidnezhad1, 2, 3, L Youssefian2, 3, S Zeinali,1 MR Barzegar,4 S Sotoudeh,2 A Ertel,3 Q Li,3 
N Mozaffari,4 P Fortina3 and J Uitto3 1 Pasteur Institute of Iran, Tehran, Iran (the Islamic 
Republic of), 2 Tehran University of Medical Sciences, Tehran, Iran (the Islamic Republic of), 
3 Thomas Jefferson University, Philadelphia, PA and 4 Shahid Beheshti University of Medical 
Sciences, Tehran, Iran (the Islamic Republic of)
Epidermolysis bullosa (EB) is a clinically and genetically heterogeneous group of heritable blistering 
diseases caused by mutations in at least 18 genes. There are 4 types of EB based on the ultrastruc-
tural level of tissue separation: EB simplex (EBS), junctional EB (JEB), dystrophic EB (DEB), and the 
Kindler syndrome. There is currently no comprehensive study about the molecular epidemiology 
of EB in Iranian populations. Clinical examination and immunofluorescence mapping showed that 
EBS, JEB, and DEB represent 13, 15, and 66% of the Iranian cohort, respectively. Due to high rate 
of consanguineous marriages these ratios are very different from EB patients in Europe and the 
US in which EBS, JEB, and DEB were reported to be 40, 27, and 33%, respectively. In the present 
study, we are assessing a cohort of 140 DEB families for pathogenic sequence alterations in the 
COL7A1 gene. Results from Sanger sequencing of 63 families show 46 distinct mutations, 23 being 
previously unreported. Among the mutations 14 were missense, 14 small indels, 4 splice-junction 
mutations, 11 nonsense, and 3 large indel mutations. Targeted sequencing of COL7A1 was also 
performed on the IonTorrent PGM, using an AmpliSeq 3-pool primer design designed to capture 
all COL7A1 exons plus 50-bp flanking regions; this approach verified the mutations discovered in a 
subset of patients by Sanger sequencing. Thirteen mutations were recurrent and found in more than 
1 family; a recurrent c.6269_6270delC (p.Pro2090LeufsX116 ) was found in 8 families. Haplotype 
analysis of the COL7A1 locus on chromosomal region 3p21.1 identified conserved haplotypes 
indicating a founder effect. Our data emphasize the need for population-specific diagnostic and 
management approaches for EB.    
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Evidence for coordinate regulation of Hmga2 and Tlr4 in hair follicle stem cells
Y Li Hormel Institute, Austin, MN
Toll-like receptor 4 (Tlr4) has emerged as a stem cell gene of interest in the mouse Ksc2 locus. 
The receptor is widely recognized as an essential element in the triggering of innate immunity, 
binding pathogen-associated molecules such as lipopolysaccharide (LPS), and initiating a cascade 
of pro-inflammatory events. However the functional role of its differential expression in hair follicle 
stem cells remains a mystery. To address the problem, we compared differential Tlr4 expression in 
keratinocytes (KCs) among Tlr4 wild type (C3H/HeOuJ), Tlr4 mutation (C3H/HeJ ; has mRNA but 
no protein) and Tlr4 deletion (C57Bl/10ScNJ ; neither mRNA nor protein) strains of mice. We found 
similar coordinate expression between Hmga2 and Tlr4 mRNA in keratinocytes between Tlr4 wild 
type and Tlr4 mutation strains (p=0.7241 for Hmga2, 0.5219 for Tlr4). As expected, no Tlr4 mRNA 
expression and low Hmga2 mRNA expression was found in unsorted Tlr4 deletion (p=0.0245 for 
Hmga2 between Tlr4 wild type and Tlr4 deletion, 0.0244 between Tlr4 mutation and Tlr4 deletion). 
After sorting with CD34 and CD49f antibodies in Tlr4 wild type and Tlr4 mutation mice, Hmga2 
expression in CD34+CD49f+ hair follicle stem cells is more than 30 times higher than that in 
CD34-CD49f+ base cells (p=0.00016 for Hmga2 between CD34-CD49f+ and CD34+CD49f+). 
Tlr4 wild type and Tlr4 mutation CD34+CD49f+ and CD34-CD49f+ KCs have significantly higher 
Hmga2 expression than in Tlr4 deletion KCs (p=0.0409 for Hmga2 between Tlr4-wild type and Tlr4 
mutation and Tlr4 deletion KCs, 0.02162 for CD34-CD49f+ KCs and 0.03639 for CD34+CD49f+ ). 
In addition, the results were confirmed with macrophages from the three stains (p=0.005 for Hmga2 
between Tlr4-non deletion and Tlr4 deletion macrophage, 0.8526 for F4/80), but no Hmga2 protein 
was observed in macrophages. These results suggest that Hmga2 mRNA is coordinately regulated 
by Tlr4 mRNA in mouse KCs and macrophage, but the mechanism must be elucidated further.   
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Mineralization of soft connective tissues and cartilage in Enpp1asj-2J mutant mice
Q Li,1 CH Pratt,2 J Zhang,1 LA Dionne,2 H Fairfield,2 SY Karst,2 JP Sundberg2 and J Uitto1 1 
Thomas Jefferson University, Philadelphia, PA and 2 The Jackson Laboratory, Bar Harbor, ME
Generalized arterial calcification of infancy (GACI), an autosomal recessive disorder caused by 
mutations in the ENPP1 gene, is characterized by extensive mineralization of the cardiovascular 
system. The affected individuals in most cases die within the first year of life, and there is currently 
no effective treatment for this disorder. In this study, we characterized a spontaneous mutant mouse, 
asj-2J, as a model for GACI. These mice were identified as part of a phenotypic deviant search in 
a large-scale production colony of BALB/cJ mice at The Jackson Laboratory. They demonstrated a 
characteristic gait due to stiffening of the joints, with phenotypic similarity to a previously charac-
terized asj (‘‘ages with stiffened joints’’) mouse, caused by a missense mutation in the Enpp1 gene. 
Complementation testing indicated that asj-2J and asj were allelic. PCR-based mutation detec-
tion strategy revealed in asj-2J mice a large, 40,035 bp, deletion spanning from intron 1 to the 
3’-untranslated region of the Enpp1 gene, coupled with a 74 bp insertion. This was accompanied 
with a significant reduction in the plasma pyrophosphate concentration and pyrophosphate to phos-
phate ratio. As a consequence, extensive ectopic mineralization affecting the arterial vasculature, 
a number of internal organs, and the dermal sheath of vibrissae, a progressive biomarker of the 
ectopic mineralization process, was demonstrated by a combination of micro-CT, histopathology 
with calcium-specific stains, and direct chemical assay of calcium. Besides soft connective tissues, 
micro-CT and histological analysis of these mice also revealed mineralization of cartilage in the ear 
pinna and trachea. Collectively, the asj-2J mouse, characterized by extensive tissue mineralization, 
serves as a novel model for GACI, a currently intractable disorder.    
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MicroRNAs involved in the pathogenesis of pachyonychia congenita
A Berroth,1 Y Cao,2 MA Flores,2 T Speaker,2 ME Schwartz,3 C Contag1 and R Kaspar2 1 
Pediatrics, Stanford University, Stanford, CA, 2 TransDerm Inc, Santa Cruz, CA and 3 
Pachyonychia Congenita Project, Salt Lake City, UT
Pachyonychia congenita (PC) is a dominant negative skin disorder caused by mutations in induc-
ible keratin genes, including KRT6A, KRT6B, KRT16 and KRT17. The major symptoms are thick-
ened dystrophic nails, leukokeratosis, and painful plantar keratoderma. To better understand PC 
pathogenesis at the molecular level, RNA profiling was performed on biopsies taken from both 
involved and uninvolved plantar skin of PC patients. 44 microRNAs were identified to be differen-
tially-expressed (≥ 2.5-fold change) in PC-involved skin. We selected 7 of these microRNAs (miR-
203, miR-135b, miR-1246, miR-31, miR-143, miR-199a, miR-199b) and analyzed their mimics 
and anti-miR inhibitors to further investigate their effects on epidermal morphology. Keratinocyte 
growth and scratch assays were performed to examine their role in proliferation and migration in 
an in vitro monolayer keratinocyte culture. Induced proliferation could be observed for miR-31, 
miR-199a, miR-199b and miR-1246 mimics in epidermal keratinocytes. Reduced proliferation 
was observed for miR-135b. Scratch assay analysis revealed that miR-203, miR-135b, miR-1246, 
miR-199a and miR-199b mimics reduced the migration rate, whereas miR-143 lead to increased 
mobility. Experiments are underway to analyze the effect of these microRNAs on skin morphology 
using 3D epidermal skin equivalents. These results suggest that the identified microRNAs have an 
influence on proliferation, migration and likely epidermal structure and might be new targets for 
the treatment of pachyonychia congenita.    
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Identification of MITF regulated microRNAs in melanoma
A Jayanthy1 and V Setaluri1, 2 1 Dermatology, University of Wisconsin-Madison, Madison, WI 
and 2 William S. Middleton Memorial Veterans Hospital, Madison, WI
Microphthalmia associated transcription factor (MITF) is the master transcriptional regulator and 
regulates several key differentiation and survival functions of melanocytes. MITF is also known to be 
a lineage addiction oncogene in a subset of melanomas and play a role in drug resistance. However, 
the precise role MITF plays in melanoma is yet to be elucidated. In order to understand the role 
of MITF in melanoma, we set out to identify MITF-regulated microRNAs. We hypothesized that a 
subset of miRNAs are differentially regulated by MITF in melanocytes and melanoma. To identify 
MITF regulated miRNAs, we first defined putative MITF promoter regions using previously published 
ChIP-seq binding data and filtered the set with experimentally verified gene expression using siRNA 
knockdown and RNA-seq. We then applied a filter for evolutionary conservation for M-box and 
identified 52 (out of 1871 known) potential MITF-regulated miRNAs. To validate regulation by MITF, 
we used ChIP-seq data to identify MITF binding within the putative promoter regions of all miRNAs 
and identified 62 miRNAs with MITF binding within the putative promoter regions. We found a 
statistically significant number of shared miRNAs between computational and ChIP-seq methods, 
suggesting that microRNAs identified by motif search and refined using evolutionary conservation 
data potentially form a group of critical MITF regulated miRNAs. Within and around many of the 
ChIP-seq identified MITF-binding regions in the DNA, we found the presence of Factorbook binding 
motifs for ~70 different transcription factors, including YY1, E2F1 and CTCF. Expression histograms 
of miRNAs containing M-boxes plotted using data from TCGA datasets showed positive skew due to 
a fraction of tumors showing greatly increased expression as compared to the rest, suggesting that a 
subset of tumors have regulatory mechanisms that cause increased expression of specific miRNAs. 
Experimental validation of subsets of these putative MITF-regulated miRNAs and their target mRNAs 
will provide important insight into the role of MITF in melanoma.    
